Summary & Overview
CPT 81459: Genomic Sequencing Procedures and Molecular Multianalyte Assays
CPT code 81459 represents genomic sequencing procedures and other molecular multianalyte assays, a cornerstone of modern molecular pathology and precision medicine. This code is widely used in laboratory settings to analyze genetic material, enabling clinicians to detect genetic anomalies, assess disease susceptibility, and inform targeted therapies. The national relevance of 81459 continues to grow as genomic testing becomes integral to patient care across specialties such as pathology, family medicine, and internal medicine.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will gain insights into payer coverage policies, clinical indications, and billing practices associated with 81459. The summary also addresses common modifiers, associated taxonomies, and relevant ICD-10 diagnoses, providing a comprehensive overview of the code's clinical and administrative context.
This publication offers benchmarks, policy updates, and a clear understanding of how 81459 fits into the broader landscape of molecular diagnostics. It is designed for healthcare professionals, billing specialists, and policy analysts seeking up-to-date information on genomic sequencing procedures and their impact on patient care and reimbursement.
CPT Code Overview
CPT code 81459 is used for genomic sequencing procedures and other molecular multianalyte assays. This code covers advanced molecular pathology and genomic testing services, which play a critical role in identifying genetic variations and guiding clinical decision-making. The typical site of service for these procedures is a laboratory setting, specifically place of service 81. These tests are essential for screening, diagnosis, and management of various genetic and chromosomal conditions, supporting precision medicine approaches across multiple specialties.
Clinical & Coding Specifications
Clinical Context
A patient presents to their primary care provider or cardiologist with a family history of cardiovascular disease or a personal history of acute myocardial infarction. The provider orders genomic sequencing procedures to assess genetic susceptibility to heart disease or to screen for chromosomal anomalies. The specimen is collected and sent to a laboratory (Place of Service 81), where molecular multianalyte assays are performed using CPT code 81459. The results may inform long-term drug therapy decisions or guide further management of atherosclerotic heart disease.
Coding Specifications
-
Modifier
26: Used when only the professional component (interpretation of results) is billed, typically by a pathologist or physician. -
Modifier
91: Used when the same clinical diagnostic laboratory test is repeated on the same patient, often to monitor changes or confirm results.
| Provider Taxonomy Code | Specialty Description |
|---|---|
207ZP0213X | Pathology - Clinical Pathology/Laboratory Medicine |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
Related Diagnoses
-
Z13.79- Encounter for other screening for genetic and chromosomal anomalies- Used when the genomic sequencing is performed for screening purposes, such as identifying genetic risk factors.
-
Z15.89- Genetic susceptibility to other disease- Indicates the patient has a genetic predisposition to certain diseases, relevant for genomic testing.
-
Z79.899- Other long term (current) drug therapy- Applied when the patient is undergoing long-term drug therapy, and genomic testing may inform medication choices.
-
I25.10- Atherosclerotic heart disease of native coronary artery without angina pectoris- Relevant when genomic testing is used to assess risk or guide management of coronary artery disease.
-
I21.9- Acute myocardial infarction, unspecified- Used when genomic testing is performed in the context of a recent myocardial infarction to evaluate genetic factors.
Related CPT Codes
81479- Unlisted molecular pathology procedure
81479 is used when a molecular pathology procedure does not have a specific CPT code. It may be used as an alternative to 81459 when the assay performed is not described by any existing CPT code. These codes are not typically billed together but may be considered in similar clinical workflows when unique or novel tests are performed.
National Reimbursement Benchmarks
For CPT code 81459, the national mean rate for BUCA (average commercial) is $2,146.05, which is substantially higher than the typical Medicare rate for similar codes, though Medicare data is not available in the input. Among commercial payers, UnitedHealth Group has the highest mean rate at $2,371.55, while Cigna is the lowest at $1,365.27.
Rate dispersion varies significantly across payers. Blue Cross Blue Shield shows the widest spread, with a difference of $2,039.00 between the 75th and 25th percentiles. Cigna also exhibits a large range of $2,167.00, indicating substantial variability in contracted rates. In contrast, Aetna has a tighter range of $886.50, suggesting more consistent reimbursement levels. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.